General (Details) $ in Thousands |
12 Months Ended | ||||
|---|---|---|---|---|---|
|
Sep. 06, 2017
USD ($)
|
Dec. 31, 2017
ILS (₪)
|
Dec. 31, 2017
USD ($)
|
Dec. 31, 2016
ILS (₪)
|
Dec. 31, 2015
ILS (₪)
|
|
| General Accounting Principal [Line Items] | |||||
| Research and development expense | ₪ 16,921,000 | $ 4,881 | ₪ 29,200,000 | ₪ 22,919,000 | |
| Rate of exchange | ₪ 3,467 | $ 1 | |||
| Securities Purchase Agreements [Member] | |||||
| General Accounting Principal [Line Items] | |||||
| Research and development expense | $ 600 | ||||
| Proceeds received from securities | $ 1,000 | ||||
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents] Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The cash inflow from current borrowings obtained. [Refer: Current borrowings] Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The amount of expenditure directly attributable to research or development activities, recognised in profit or loss. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|